Pediatrics · Growth DisordersTrial Updatecompetitivemid-term

BioMarin's Study on Growth in Children with Idiopathic Short Stature Underway

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 12:32:31 AM

Assessment confidence: 79% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

BioMarin's ongoing study on idiopathic short stature is significant as it may yield critical insights into growth patterns that could shape future treatment strategies. The outcomes of this trial could alter competitive dynamics in the pediatric growth disorder market. Regulatory context from FDA (FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this study as it could influence BioMarin's strategy in pediatric growth disorder treatments. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sub-indication match (ild); sponsor/company relevance (novartis). In ild, 7 regulatory and 0 competitive items passed relevance filtering for BioMarin Pharmaceutical.

Competitive Pressure

The most relevant competitive pressure comes from This study may position BioMarin to better understand growth patterns and inform future treatments for ISS, impacting competitive dynamics in pediatric growth therapies..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL) (FDA). Sub-indication match (ild); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA, PMDA. The study is primarily focused on data collection and does not directly impact regulatory approvals at this stage.

Key Opportunities

Depending on the findings, BioMarin could enhance its market position in pediatric growth therapies, potentially affecting market share and revenue for competitors.
Portfolio teams should monitor the outcomes of this study as it could influence BioMarin's strategy in pediatric growth disorder treatments.

What Would Change This Assessment

This becomes more urgent if Key milestones include data collection completion and initial findings on growth measurements.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S ZYRTEC HIVES (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View source
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
PMDAhigh relevance
Sub-indication match (ild)
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View source
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sub-indication match (ild); Sponsor/company relevance (Novartis)
FDA document
View source
Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: Randomized Controlled Trial
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source
Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Can a scientific approach to induction of labor using hyoscine butyl bromide (HBB) concomitantly with prostaglandins shorten the duration of time to reach active stage of labor? A cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

BioMarin Pharmaceutical
pediatric growth therapies

Commercial impact

medium

Depending on the findings, BioMarin could enhance its market position in pediatric growth therapies, potentially affecting market share and revenue for competitors.

Regulatory impact

low

The study is primarily focused on data collection and does not directly impact regulatory approvals at this stage.

What to watch

Key milestones include data collection completion and initial findings on growth measurements.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.